CONTACT US: Contact info
|
Citation |
Galluzzo M, D'Adamio S, Massaro A, Piccolo A, Bianchi L, Talamonti M. Clin. Cosmet. Investig. Dermatol. 2019; 12: 311-321. |
|
Copyright |
(Copyright © 2019, Dove Medical Press) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab). © 2019 Galluzzo et al. Language: en |
|
Keywords |
human; suicide; systematic review; suicidal ideation; depression; suicidal behavior; Psoriasis; fatigue; vomiting; unclassified drug; neutropenia; headache; drug mechanism; nonhuman; drug safety; sepsis; drug efficacy; diarrhea; nausea; cardiovascular disease; infection; arthralgia; drug response; drug indication; Atopic dermatitis; regulatory mechanism; Article; injection site reaction; eczema; upper respiratory tract infection; respiratory tract infection; psoriasis vulgaris; atopic dermatitis; candidiasis; rhinopharyngitis; Biologics; phase 2 clinical trial (topic); phase 3 clinical trial (topic); secukinumab; ustekinumab; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Anti-IL17RA; brodalumab; Brodalumab; interleukin 17; interleukin 17 receptor; interleukin 17 receptor A; interleukin 17C; interleukin 17F; ixekizumab; major adverse cardiac event; oropharynx candidiasis; PASI100 |